Method of Identifying Patients Suitable for High-Dose Cyclophosphamide Treatment

Aldehyde dehydrogenases (ALDHs) are intracellular enzymes responsible for oxidizing aldehydes. A number of studies seem to suggest that ALDH confers resistance of cells to cyclophosphamide, which is routinely used for the treatment of autoimmune diseases and cancer. High dose cyclophosphamide therapy appears to be more effective than the low-dose therapy, although high dose cyclophosphamide therapy is not suitable for all patients because of higher toxicity. It is generally difficult to predict which patients might be suitable for high-dose cyclophosphamide, which results in a high mortality rate associated with high-dose cyclophosphamide treatment. Scientists at JHU have discovered that ALDH may be used as an indicator for identifying patients that are suitable for high-dose cyclophosphamide treatment. This invention will be especially useful in decreasing patient mortality associated with high-dose cyclophosphamide treatment. Description (Set) Proposed Use (Set) The present invention may be used to identify patients who are able to tolerate high dose cyclophosphamide treatment commonly used in the treatment of cancer and autoimmune disease. By doing so, this invention may reduce the number of deaths associated with high-dose cyclophosphamide treatment.

Inventor(s): Brodsky, Robert A.

Type of Offer: Licensing

Next Patent »
« More Medical Patents

Share on      

CrowdSell Your Patent